Status:
COMPLETED
Plasma S-adenosylhomocysteine Levels and Endothelial Dysfunction
Lead Sponsor:
Shenzhen Center for Disease Control and Prevention
Collaborating Sponsors:
Peking University Shenzhen Hospital
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
18-60 years
Brief Summary
To investigate the relationship betweeen plasma S-adenosylhomocysteine (SAH) levels and endothelial dysfunction, we plan to enroll approximately 150 patients with high risk of cardiovascualr disease,w...
Detailed Description
To investigate the relationship betweeen plasma S-adenosylhomocysteine (SAH) levels and endothelial dysfunction, we plan to enroll approximately 150 patients with high risk of cardiovascualr disease,w...
Eligibility Criteria
Inclusion
- patients who have stable clinical conditions, except for acute coronary syndromes, and the availability of measurement of flow-mediated dilation, or have more than three cardiovascular traditional risk factors, such as smoking, alcohol use, obesity, hypertesion, diabetes, family history, and so on.
Exclusion
- critical illness or hemodynamic instability other than acute coronary syndromes, surgery, or trauma within the previous month, known cancer, hepatic failure or hepatitis, or the use of drugs, such as anticancer agents, which would affect plasma tHcy concen-trations.
Key Trial Info
Start Date :
December 4 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2018
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03345927
Start Date
December 4 2017
End Date
April 30 2018
Last Update
March 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chun Wang
Shenzhen, Guangdong, China, 518055